Welcome to US Medical Affairs Oncology
Welcome to US Medical Affairs Oncology
Start Exploring
Welcome to Bayer's Medical Affairs Oncology Platform!
The Oncology portfolio continues to expand! Our oncology portfolio is dedicated to addressing both solid and liquid tumors, featuring six approved therapies across eleven indications.
Bayer is committed to delivering science for a better life by advancing a portfolio of innovative treatments. The oncology franchise at Bayer includes
marketed products and several other assets in various stages of clinical development and across a range of research areas: Tumor intrinsic pathways,
next-generation immuno-oncology, and targeted radionuclide therapies. Together, these products reflect the company’s approach to research, which
prioritizes targets and pathways with the potential to impact the way that cancer is treated.
Our oncology pipeline is strategically focused on meeting the significant unmet needs of patients while fostering sustainable growth in the rapidly evolving oncology market. We are committed to investing in the advancement of precision medicine, with several active programs in the precision medicine space as well as an expansive immuno-oncology portfolio. This dedication aligns with our core value of "Science for a better life".
Follow Us
